Predicta Biosciences raised $5.2M in a seed round led by The Engine Ventures to transform the diagnosis, treatment and monitoring of blood cancers.

Jul 16, 2024•over 1 year ago

Amount Raised

$5.2 Million

Round Type

seed

CambridgeBiotechnologyHealth Care

Investors

Oetgen FamilyAmerican Cancer Society Bright EdgeTime Boost CapitalIllumina VenturesThe Engine Ventures

Description

Predicta Biosciences, a precision oncology company, announced an oversubscribed $5.2 million seed round led by The Engine Ventures, with additional participation from Illumina Ventures, Time Boost Capital, the American Cancer Society Bright Edge, and the Oetgen family. The company will use the seed funding to expand its team, and build a CLIA lab and workflow for sequencing and bioinformatics.

Company Information

Company

Predicta Biosciences

Location

Cambridge, Massachusetts, United States

About

Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns